Oct 20, 2015 • 8:05 am EDT Corbus Pharmaceuticals Announces FDA Orphan Drug Designation and Fast Track Status of Resunab(TM) for the Treatment of Cystic Fibrosis
Oct 15, 2015 • 7:30 am EDT Corbus Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of Resunab(TM) for Treatment of Cystic Fibrosis
Oct 7, 2015 • 7:05 am EDT Corbus Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of Resunab for Systemic Sclerosis
Sep 22, 2015 • 7:00 am EDT Corbus Pharmaceuticals to Present Additional Data on the Effects of Resunab(TM) in the Treatment of Pulmonary Infection and Inflammation in Pre-Clinical Models of Cystic Fibrosis
Sep 21, 2015 • 7:00 am EDT Corbus Pharmaceuticals Commences Patient Enrollment in Phase 2 Clinical Study of Resunab(TM) for the Treatment of Cystic Fibrosis
Aug 31, 2015 • 8:05 am EDT Corbus Pharmaceuticals Commences Patient Enrollment in Phase 2 Clinical Study of Resunab(TM) for the Treatment of Systemic Sclerosis
Aug 27, 2015 • 8:05 am EDT Corbus Pharmaceuticals Successfully Completes Warrant Call -- Raises $11.3 mm in Total From 100% Exercise of Callable Warrants
Aug 19, 2015 • 7:35 am EDT Corbus Pharmaceuticals' Investigational Drug Resunab(TM) Granted Fast Track Status by the U.S. FDA for the Treatment of Systemic Sclerosis